EXAI · Exscientia
Acquired Company
Recursion acquired Exscientia on 11/20/2024.
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Exscientia's pipeline of internal and partnered programmes demonstrates its ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials. Exscientia has offices in Oxford, Vienna, Dundee, Miami, Boston, and Osaka.
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$4.84
Open
$4.84
Volume
N/A
Day Range
$4.84 - $4.84
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
25.90%
Institutional Own.
20.81%
Qtr Updated
Sep 30th 2024
